BriaCell Starts Patient Enrollment In First-in-Human Study Of Bria-OTS In Advanced Metastatic Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
BriaCell Therapeutics Corp. (NASDAQ:BCTX) has initiated a first-in-human, Phase 1/2 study to evaluate the safety and efficacy of Bria-OTS™, its personalized off-the-shelf next-generation immunotherapy, in advanced metastatic breast cancer. The study will assess Bria-OTS™ as a monotherapy and in combination with the PD-1 inhibitor tislelizumab.
May 30, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BriaCell Therapeutics has started a Phase 1/2 study for its Bria-OTS™ immunotherapy in advanced metastatic breast cancer. This could potentially lead to positive clinical outcomes and increased investor interest.
The initiation of a clinical trial for a novel cancer therapy is a significant milestone for a biotech company. Positive results could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100